Back to top
more

Innoviva (INVA)

(Delayed Data from NSDQ)

$15.98 USD

15.98
750,994

+0.14 (0.88%)

Updated May 16, 2024 04:00 PM ET

After-Market: $15.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (189 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.

Top Ranked Value Stocks to Buy for April 23rd

Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 23rd.

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Innoviva's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Innoviva.

Top Ranked Value Stocks to Buy for April 16th

Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 16th

Top Ranked Momentum Stocks to Buy for April 16th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 16th

Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day

Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day

Sejuti Banerjea headshot

Another Drug to Fight Coronavirus & 3 Picks

Another drug is being tested to kill the virus (if we can figure out administration on humans).

Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Sanofi (SNY) Catches Eye: Stock Jumps 5.3%

Sanofi (SNY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 6th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Madhurima Das headshot

5 Stocks to Grab as Gold Prices Surge on Coronavirus Fears

Gold prices are currently at seven-year highs as investors are flocking to buy gold amid fears of the coronavirus outbreak and economic slowdown.

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.

Innoviva (INVA) Outpaces Stock Market Gains: What You Should Know

Innoviva (INVA) closed at $13.91 in the latest trading session, marking a +0.87% move from the prior day.

Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease

Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.

BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

Alnylam Stock Up More Than 61% YTD on Pipeline Progress

Shares of Alnylam (ALNY) rise on significant pipeline progress.

Top Ranked Value Stocks to Buy for December 30th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 30th.

Innoviva (INVA) Stock Moves -0.84%: What You Should Know

Innoviva (INVA) closed at $14.25 in the latest trading session, marking a -0.84% move from the prior day.

Top Ranked Value Stocks to Buy for December 26th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 26th.

AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod

AstraZeneca (AZN) gets approval in China for PT010, its triple-combo inhaler, a fixed-dose ICS/LABA/LAMA inhaler, to treat COPD.

Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris

Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.

Top Ranked Value Stocks to Buy for December 20th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 20th.

Epizyme Stock Up on Positive Advisory Votes for Tazemetostat

Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.